<DOC>
	<DOCNO>NCT00949078</DOCNO>
	<brief_summary>The purpose study determine treatment omalizumab ( Xolair , anti-IgE ) eliminate reduce symptom peanut allergy .</brief_summary>
	<brief_title>Omalizumab Treatment Peanut Allergy</brief_title>
	<detailed_description>The study evaluate omalizumab effective treatment peanut allergy . In addition evaluate role allergic cell ( mast cell basophil ) IgE food allergy .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Food Hypersensitivity</mesh_term>
	<mesh_term>Peanut Hypersensitivity</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Male Female ( nonpregnant ) , age 1850 Females must : Surgically sterile ( hysterectomy , bilateral oophorectomy , bilateral tubal ligation ) , OR postmenopausal ( least 1 year since last menses ) , OR use one follow medically acceptable form birth control throughout duration study : Systemic contraceptives Diaphragm intravaginal spermicide Cervical cap Intrauterine device Condom intravaginal spermicide Females certain category ( sexually active , vasectomized partner ) admit discretion investigator casebycase basis . Females , exclude 1 year postmenopausal surgically sterile , must negative urine pregnancy test Visit 1 visit specify protocol . If subject becomes pregnant study participation , discharge study follow adverse event termination pregnancy delivery complete . Given drug pregnancy category B , follow pregnant mother adverse event duration study . Physician diagnose peanut allergy OR convince clinical history peanut allergy onset early childhood . Positive puncture skin test peanut great equal 3 mm diluent control Positive ImmunoCAP peanut â‰¥0.35 kU/L . In vitro basophil responsiveness peanut allergen , great 20 % histamine release 1019 % great 50 % optimal antiIgE response ( baseline visit ) . Subjects must positive oral food challenge peanut define objective sign clear allergic reaction cumulative dose peanut protein &lt; 1000 mg . Objective allergic sign may include oral urticaria , cutaneous urticaria , rhinorrhea , sneeze , cough , wheeze , vomit . Asthma FEV1 &lt; 80 % predict severe persistent asthma per NAEP Standards ( 2007 National Asthma Education Prevention Program Expert Panel Report III guideline ) poorly control asthma oral corticosteroid use exacerbation last 6 month . History severe allergic reaction peanut require intubation ICU admission . Late onset peanut allergy , defined subject previously tolerate peanut regular basis initial reaction . Patients biopsy proven eosinophilic enteropathy exclude . Patients total serum IgE level less 30 IU/mL great 700 IU/mL time enrollment exclude . Patients hematocrit &lt; 32 % , WBC count &lt; 4000/microliter , platelet &lt; 75000/microliter , creatinine &gt; 141.4 micromolar/L , AST &gt; 100 IU/L exclude abnormality present time enrollment . Body weight less 30 kg great 150 kg enrollment exclude . Patients plan become pregnant breastfeed exclude study . Patients must indicate use method avoid pregnancy . Other significant medical condition ( e.g. , liver , gastrointestinal , kidney , cardiovascular , pulmonary disease , blood disorder ) , , opinion Investigator , make subject unsuitable induction food reaction . Current prior use omalizumab past 12 month . Use nontraditional form allergen immunotherapy ( e.g. , oral sublingual ) immunomodulator ( include corticosteroid ) biologic therapy within past year . Use betablockers ( oral ocular ) , angiotensinconverting enzyme ( ACE ) inhibitor , angiotensinreceptor blocker ( ARB ) within 72 hour prior either qualification OFC . Use antihistamine ( within 3 day short act 5 day long act ) prior screen OFC . Use antihistamine ( within 3 day short act 5 day long act ) prior study OFC . These procedure reschedule antihistamine require time . Inability discontinue antihistamine routine study test . History ischemic cardiovascular disease ( i.e. , previous MI , angina etc ) uncontrolled hypertension . Significant upper respiratory tract infection ( URI ) within 7 day OFC ; OFCs reschedule within 7 day follow resolution URI . Mental illness history drug alcohol abuse , opinion investigator , would interfere participant 's ability comply study requirement . Inability unwillingness participant give write informed consent comply study protocol . Use investigational drug within 8 week participation . Any contraindication omalizumab include patient previous hypersensitivity omalizumab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>peanut</keyword>
	<keyword>allergy</keyword>
</DOC>